A Systematic Overview of Chemotherapy Effects in B-cell Chronic Lymphocytic Leukaemia

References

• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34. (0)
   Google Scholar
• Binet JL, Catovsky D, Chandra P, et al. Proposal for a revised prognostic staging system, Report from the in-ternational workshop on CLL. Br J Hematol 1981; 98: 365-8. (0)
   Google Scholar
• Han T, Ezdinli EZ, Shimaoka K, et al. Chlorambucil vs combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia Cancer 1973; 31: 502–8. (C3/26)
   Google Scholar
• Idestrom K, Kimby E, Bjorkholm M, et al. Treatment of chronic lymphocytic leukemia and well-differentiated lymphocytic lymphoma with continuous low or intermittent high-dose prednimustine vs chlorambucil/ prednisolone. Eur J Cancer Clin Oncol 1982; 18: 1117-23. (C2/118)
   Google Scholar
• Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil vs Binet's modified Cyclophosphamide, doxorubicin, vin-cristine, and prednisone in the treatment of patients with advanced B-chronic lymphocytic leukemia. Result of an inter-national multicenter randomised trial. Cancer 1997; 79: 2107-14. (C1/228)
   Google Scholar
• Knospe WH, Loeb V Jr, Huguley CM Jr. Bi-weekly chloram-bucil treatment of chronic lymphocytic leukemia. Cancer 1974; 33: 555-62. (C3/58)
   Google Scholar
• Sawitsky A, Rai KR, Glidewell O, et al. Comparison of daily vs intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049-59. (C2/96)
   Google Scholar
• Catovsky D, Richards S, Fooks J, et al. CLL Trials in the United Kingdom. The Medical Research Council CLL trials 1, 2 and 3. Leukemia Lymphoma 1991; (Suppl 1): 105–12. (C1/660, C1/640, C3/90) (489 patients in trials comparing addition of prednisone, 306 patients in trials evaluating de-ferred therapy).
   Google Scholar
• Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia French Cooperative Group on Chronic Lymphocytic Leukaemia. New Engl J Med 1998; 338: 1506-14. (C1/926)
   Google Scholar
• French Cooperative Group on Chronic Lymphocytic Leukaemia (CLL-80). Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A). Blood 1990; 75: 1414-21. (C1/609)
   Google Scholar
• Brugiatelli M, Jaksic B, Planinc-Peraica A, et al. Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long term results of a randomised trial. Eur J Haema-tol 1995; 55: 158-63. (C3/148)
   Google Scholar
• Keating M, Lerner S, O'Brien S. Long term results with Fludarabine in CLL. Hematol Cell Therapy 1997; 39 (Suppl 1): 57–8. (P1/375)
   Google Scholar
• Cheson BD, Bennett JM, Greyer M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukaemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-7. (0)
   Google Scholar
• Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiv-ing fludarabine regimens as initial therapy. Blood 1998; 92: 1165-71. (P1/174)
   Google Scholar
• Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxy- adenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996; 7: 373-9. (P2/52)
   Google Scholar
• Piro LD, Carrera CJ, Beutler E, et al. 2-chloro-deoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069-73. (0)
   Google Scholar
• Delannoy A, Martiat P, Gala JL, et al. 2-Chlorodeoxyadeno-sine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130-5. (P3/19)
   Google Scholar
• Juliusson G, Christiansen I, Hansen MM, et al. Oral cladrib-Me as primary therapy for patients with B-cell chronic lymphocytic leukemia J Clin Oncol 1996; 14: 2160–6. (P1/63)
   Google Scholar
• Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxya-denosine activity in patients with untreated chronic lymphocytic leukemia J Clin Oncol 1995; 13: 570–4. (P3/20)
   Google Scholar
• Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-9. (P2/33)
   Google Scholar
• Rai KR, Elias L, Shephard J, et al. A randomised comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia Hematol Cell Ther-apy 1997; 39 (Suppl 1): Abstr 58. (C3/544)
   Google Scholar
• Jaksic B, Delmer A, Brugiatelli M, et al. Interim analysis of a randomised EORTC study comparing high dose chlorambucil vs fludarabine in untreated B-cell chronic lymphocytic leukemia. Hematol Cell Therapy 1997; 39 (Suppl 1): Abstr 87. (C3/52 ongoing)
   Google Scholar
• CLL Trialists' Collaborative Group. Chemotherapeutic op-tions in chronic lymphocytic leukemia: a meta-analysis of randomised trials. J Natl Cancer Inst 1999; 91: 861-8. (M1/ 2048)
   Google Scholar
• Shustik C, Mick R, Silver R, et al. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil vs observa-tion. Hematol Oncol 1988; 6: 7-12. (C3/59)
   Google Scholar
• Spanish Cooperative Group Pethema. Treatment of chronic lymphocytic leukemia Leukemia Lymphoma 1991; (Suppl 4): 89–91. (C3/96)
   Google Scholar
• French Cooperative Group on Chronic Lymphocytic Leukaemia. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. Br J Haematol 1989; 73: 334-40. (C3/70)
   Google Scholar
• French Cooperative Group on Chronic Lymphocytic Leukaemia. Is the CHOP regimen a good treatment for advanced CLL? Leukemia Lymphoma 1994; 13: 449-56. (C1/287)
   Google Scholar
• Hansen MM, Andersen E, Birgens H, et al. CHOP vs pred-nisolone chlorambucil in chronic lymphocytic leukemia. Leukemia Lymphoma 1991; 5: 97-100. (C2/200)
   Google Scholar
• Kimby E, Mellstedt H. Chlorambucil /prednisone vs CHOP in symptomatic chronic lymphocytic leukemias of B-cell type. Leukemia Lymphoma 1991; 5: 93-7. (C2/116)
   Google Scholar
• Johnson S, Smith AG, Loeffler H, et al. Multicentre prospec-tive randomised trial of fludarabine vs cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of ad-vanced-stage chronic lymphocytic leukaemia. The French Co-operative Group on CLL. Lancet 1996; 347: 1432-8. (C1/196)
   Google Scholar
• Leporrier M, Chevret S, Cazin B, et al. Randomised compari-son of fludarabine, CAP and CHOP in 695 previously un-treated stage B and C CLL. Blood 1997; 90 (Suppl 1) 2357: Abstr 529. (C3/695)
   Google Scholar
• Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-84. (P1/191)
   Google Scholar
• Partyka S, Lerner S, O'Brien S, et al. First salvage therapy for patients relapsing or refractory after having received fludara-bine for chronic lymphocytic leukemia (CLL). Hematol Cell Therapy 1997; 39 (Suppl 1): Abstr 89. (P3/130)
   Google Scholar
• Rummel M, Schenk M, Renner C, et al. Fludarabine and epirubicin in the treatment of CLL: a German multicenter phase II study. Ann Oncol 1999; 10: 183-8. (P2/38)
   Google Scholar
• Mauro FR, Foa R, Crescenzi S, et al. Combination of fludarabine, ara-C, mitoxantrone and dexamethasone for the treatment of advanced chronic lymphocytic leukemia Hema-tol Cell Therapy 1997; 39 (Suppl 1): Abstr 88. (P3/17)
   Google Scholar
• Bosch F, Perales M, Cobo F, et al. Fludarabine, cyclophos-phamide and mitoxantrone therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma. Blood 1997; 90: (Suppl 1): Abstr 2360. (P3/32)
   Google Scholar
• Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia Ann Int Med 1996; 124: 311–5. (R2/54)
   Google Scholar
• Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748-58. (P2/22)
   Google Scholar
• Bartlett-Paudite I, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for B-cell CLL: Balance between toxicity and efficacy. Blood 1994; 84 (Suppl 1): Abstr 536. (P3/45)
   Google Scholar
• Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366-76. (P2/20)
   Google Scholar
• Khouri I, Keating M, Körbling M, et al. Transplant-Lite: Induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24. (P3/15)
   Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytore-duction for the treatment of malignant and non-malignant disease. Blood 1998; 91: 756-63. (P2/26)
   Google Scholar
• Sutton L, Maloum K, Cosset J, et al. Autologous stem cell transplantation (ASCT) as salvage treatment for advanced B-chronic lymphocytic leukemia (CLL). EBMT 1998; Abstr 270. (P3/18)
   Google Scholar
• Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukemia: a chance for cure? Br J Cancer 1998; 77: 2291-7. (P2/20)
   Google Scholar